<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>04347naa a22005777i 4500</leader>
  <controlfield tag="001">UMUN-OA-20261005-MLS-059</controlfield>
  <controlfield tag="003">local</controlfield>
  <controlfield tag="005">20261005174906.0</controlfield>
  <controlfield tag="006">m     o  d        </controlfield>
  <controlfield tag="007">cr||||||||||||</controlfield>
  <controlfield tag="008">261005s2024    xx      o    u000 0 eng d</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="a">10.32604/or.2024.050350</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(local)EuropePMC:PMC11209743</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">local</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">local</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1="0" ind2=" ">
    <subfield code="a">Paulina Chmiel</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment. /</subfield>
    <subfield code="c">Paulina Chmiel; Aleksandra S&#x142;OWIKOWSKA; &#x141;ukasz Banaszek [and others].</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
    <subfield code="a">[Place of publication not identified] :</subfield>
    <subfield code="b">Tech Science Press,</subfield>
    <subfield code="c">2024.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 online resource (1 article).</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
    <subfield code="a">text</subfield>
    <subfield code="b">txt</subfield>
    <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
    <subfield code="a">computer</subfield>
    <subfield code="b">c</subfield>
    <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
    <subfield code="a">online resource</subfield>
    <subfield code="b">cr</subfield>
    <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publication type: Review article.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Linked open-access copy: published version.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Open access; no subscription required for the linked open-access version.</subfield>
    <subfield code="f">Unrestricted online access</subfield>
    <subfield code="2">star</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution. See the linked licence for the applicable terms.</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/</subfield>
  </datafield>
  <datafield tag="546" ind1=" " ind2=" ">
    <subfield code="a">In English.</subfield>
  </datafield>
  <datafield tag="588" ind1="0" ind2=" ">
    <subfield code="a">Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">Course allocation: B. Sc. Medical Laboratory Science.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Anaplastic Lymphoma Kinase (Alk)</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Inflammatory Myofibroblastic Tumor (Imt)</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Tyrosine Kinase Inhibitors (Tki)</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Epithelioid Inflammatory Myofibroblastic Sarcoma</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">B. Sc. Medical Laboratory Science</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">UMUN open access collection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">molecular diagnostics</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">Review articles.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Aleksandra S&#x142;OWIKOWSKA</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">&#x141;ukasz Banaszek</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Anna Szumera-CIE&#x107;KIEWICZ</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">BART&#x142;OMIEJ Szostakowski</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Mateusz J SPA&#x142;EK</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Tomasz &#x15A;witaj</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Piotr Rutkowski</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Anna M Czarnecka</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="t">Oncology research</subfield>
    <subfield code="g">Vol. 32, no. 7, (2024), pages/article 1141-1162</subfield>
    <subfield code="x">0965-0407</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">https://europepmc.org/articles/PMC11209743</subfield>
    <subfield code="y">Read open-access publication</subfield>
    <subfield code="z">Open access.</subfield>
    <subfield code="7">0</subfield>
  </datafield>
  <datafield tag="884" ind1=" " ind2=" ">
    <subfield code="a">Course selection and automated MARC21 enrichment from Europe PMC metadata.</subfield>
    <subfield code="g">20261005</subfield>
    <subfield code="k">https://europepmc.org/articles/PMC11209743</subfield>
    <subfield code="q">local</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="n">0</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">1201</subfield>
    <subfield code="d">1201</subfield>
  </datafield>
</record>
